CRVS Company Profile and Key Details

Q: Who are the executives of CRVS?

Dr. Peter A. Thompson FACP, M.D.Co-Founder & Independent ChairmanMr. Alan C. Mendelson Esq.Sec.Dr. Erik J. Verner Ph.D.Co-FounderDr. Richard A. Miller M.D.Co-Founder, Pres, Chief Executive Officer & ChairmanMr. Leiv LeaChief Financial OfficerDr. William Benton Jones Ph.D.Senior Vice President of Pharmaceutical Devel.Dr. James T. Rosenbaum M.D.Senior Vice President of Research

NASDAQ : CRVS

Corvus Pharmaceuticals

$12.92

-0.15-1.15%

At Close 4:00 PM

58.43

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Corvus Pharmaceuticals, Inc. (CRVS) stock surged +3.02%, trading at $13.31 on NASDAQ, up from the previous close of $12.92. The stock opened at $12.97, fluctuating between $12.53 and $13.34 in the recent session.

Stock Snapshot

12.92

Prev. Close

1.12B

Market Cap

12.53

Day Low

-25.6

P/E Ratio

-0.52

EPS (TTM)

-0.49

Cash Flow per Share

12.97

Open

84.09M

Number of Shares

13.34

Day High

76.97%

Free Float in %

0.79

Book Value

819.53K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 27, 2026	13.17	13.51	12.91	12.92	844.59K
Jul 24, 2026	13.75	13.88	13.04	13.07	955.87K
Jul 23, 2026	13.64	13.91	13.48	13.68	999.37K
Jul 22, 2026	14.38	14.57	13.90	13.99	541.79K
Jul 21, 2026	14.12	14.57	14.05	14.47	664.42K
Jul 20, 2026	14.95	15.20	14.08	14.10	656.65K
Jul 17, 2026	13.98	15.20	13.90	14.90	780.72K
Jul 16, 2026	14.68	14.80	13.98	14.27	1.26M
Jul 15, 2026	14.94	15.29	14.71	14.92	878.14K
Jul 14, 2026	14.72	14.99	14.31	14.97	1.43M
Jul 13, 2026	15.28	15.59	14.69	14.71	1.49M
Jul 10, 2026	16.11	16.20	15.27	15.67	1.21M
Jul 09, 2026	16.01	16.47	15.95	16.20	1.07M
Jul 08, 2026	15.53	16.37	15.53	16.08	2.61M
Jul 07, 2026	15.30	15.88	14.93	15.63	1.34M
Jul 06, 2026	15.20	15.70	15.17	15.17	1.09M
Jul 02, 2026	14.78	15.50	14.58	15.23	1.32M
Jul 01, 2026	14.74	15.86	14.66	14.76	2.09M
Jun 30, 2026	14.53	14.98	14.30	14.94	1.5M
Jun 29, 2026	13.39	14.50	13.32	14.48	1.49M

Contact Details

South San Francisco, CA 94010

United States

https://www.corvuspharma.com 650 900 4520

About Company

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.

Stock Peers

ARGX

-29.4-3.20%

argenx SE$888.82 REGN

11.16+1.70%

Regeneron Pharmaceuticals, Inc.$667.17 MDGL

6.74+1.24%

Madrigal Pharmaceuticals, Inc.$551.25 UTHR

-0.53-0.10%

United Therapeutics Corporation$527.94 VRTX

1.64+0.34%

Vertex Pharmaceuticals Incorporated$479.00 KRYS

16.63+4.96%

Krystal Biotech, Inc.$351.82 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

BeOne Medicines AG$325.90 PRAX

-9.5-2.92%

Praxis Precision Medicines, Inc.$315.80 LGND

-3.03-1.01%

Ligand Pharmaceuticals Incorporated$297.50

Company Overview

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) closed at $13.31 USD, gaining $0.39 (3.02%) from the previous close of $12.92. The stock is currently mid-range between its 52-week high and low $3.96 and $26.95. With a market capitalization of about $1.12 billion, Corvus Pharmaceuticals, Inc. is classified as a small-cap and shows market-like volatility (beta ~0.82). Key stats such as the average daily volume over the past year has been around 1.48 million shares, volume is running light vs its 52-week average. Headquartered in South San Francisco, CA, Corvus Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Richard A. Miller, the company employs approximately 37 people and listed since March 23, 2016. Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies.

Technical Performance

CRVS has shown sold momentum, gaining 217.19% over the past week and 204.12% over the past quarter, though year-to-date performance is up 178.05%. Short-term trend indicators are bearishly aligned (SMA20 -4.55%, SMA50 28.31%, SMA200 130.48%). The stock’s 14-day RSI is 53.9 (neutral), while the ATR of 1.36 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -32.24% below its high and over 618.9% above its low. Average 10-day trading volume of 777.12 thousand shares is below the 3-month average of 1.46 million, indicating normal recent market interest.

Valuation Metrics

Corvus Pharmaceuticals, Inc. trades at a P/E ratio of -23.87, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.91 trading at moderately above to book value. The P/FCF stands at -31.42, also below market averages.

Dividend & Fair Value

Corvus Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.05. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Corvus Pharmaceuticals, Inc. generated EPS of -$0.53 over the past year. Five-year average earnings growth is 8.47%. Wall Street analysts project EPS growth of 10.79% annually over the next five years. The latest quarter delivered EPS of -$0.15. The next quarter is forecast at -$0.13. Next year's EPS is expected at $9.59. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $42.00 to $16.00. The high target offers 225.08% upside. The low target suggests 23.84% downside. The mean target is $31.14. This offers 141.02% upside. Corvus Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 7.14%. The prior quarter beat by 7.14%. Over the last six quarters, Apple has recorded several small beats. These include 50.0% in March 25, 2025.

Shareholding & Insider Activity

Corvus Pharmaceuticals, Inc. has 84.09 million shares outstanding. The public float is 72.76 million shares, elevated short interest at 24.42% of float. This equals 18.06 million shares. The short ratio is 12.38 days. Institutional investors hold 88.65% of the float. Insiders own 3.51%. ORBIMED ADVISORS LLC holds 7.17 million shares, Thompson Peter A. has 7.17 million shares and Novo A/S has 3.22 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Corvus Pharmaceuticals has not generated any revenue. Returns are negative, with ROA at -59.34% and ROE at -69.87%.
On valuation metrics, Corvus Pharmaceuticals trades at a P/E of -23.87, P/S of 0.00 and P/B of 4.91. The current ratio is 19.81 and quick ratio is 19.81. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -31171.00 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -41.86.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Corvus Pharmaceuticals posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $151.00K (margin 0.00%). Operating income was - $23.41M (margin 0.0%). Net income was- $27.03M (EPS - $0.56).
The company ended the quarter with $27.15M in cash and short-term investments, a total debt of $1.37M, and net debt of - $11.25M. Total assets were $45.55M, with equity of $38.68M. Financials further reflected weakness, with operating cash flow of - $23.94M, free cash flow of - $23.97M, and capital expenditures of - $34.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Corvus Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -14.94%, with price expected at $10.99 by August 10, 2026, within a range of $10.41 to $11.65 3-Month Outlook: Projected rise of 39.71%, reaching $18.05 by October 23, 2026, with a range of $17.59 to $18.53. 1-Year Outlook: Projected gain of 130.88%, with price at $29.83 by July 27, 2027, within a range of $31.00 to $35.75.

Key Takeaways

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) shares are up 178.05% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Corvus Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -23.87. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $14.88, suggesting 15.17% upside. Our AI forecast model points to short-term weakness (-14.94% over two weeks), a medium-term rise (39.71% over three months), and a longer-term gain (130.88% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Corvus Pharmaceuticals, Inc. (CRVS) stock price?

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) stock price is $13.31 in the last trading session. During the trading session, CRVS stock reached the peak price of $13.34 while $12.53 was the lowest point it dropped to. The percentage change in CRVS stock occurred in the recent session was 3.02% while the dollar amount for the price change in CRVS stock was $0.39.

CRVS's industry and sector of operation?

The NASDAQ listed CRVS is part of Biotechnology industry that operates in the broader Healthcare sector. Corvus Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CRVS?

Dr. Peter A. Thompson FACP, M.D.
Co-Founder & Independent Chairman
Mr. Alan C. Mendelson Esq.
Sec.
Dr. Erik J. Verner Ph.D.
Co-Founder
Dr. Richard A. Miller M.D.
Co-Founder, Pres, Chief Executive Officer & Chairman
Mr. Leiv Lea
Chief Financial Officer
Dr. William Benton Jones Ph.D.
Senior Vice President of Pharmaceutical Devel.
Dr. James T. Rosenbaum M.D.
Senior Vice President of Research

How CRVS did perform over past 52-week?

CRVS's closing price is 226.26% higher than its 52-week low of $3.96 where as its distance from 52-week high of $26.95 is -52.06%.

How many employees does CRVS have?

Number of CRVS employees currently stands at 37.

Link for CRVS official website?

Official Website of CRVS is: https://www.corvuspharma.com

How do I contact CRVS?

CRVS could be contacted at phone 650 900 4520 and can also be accessed through its website. CRVS operates from 863 Mitten Road, South San Francisco, CA 94010, United States.

How many shares of CRVS are traded daily?

CRVS stock volume for the day was 819.53K shares. The average number of CRVS shares traded daily for last 3 months was 1.48M.

What is the market cap of CRVS currently?

The market value of CRVS currently stands at $1.12B with its latest stock price at $13.31 and 84.09M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	37
Beta	0.82
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CRVS Company Profile and Key Details

Corvus Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook